Characteristic at the time of initial brain metastasis | No. of patients (%) |
---|---|
Median age (range), years | 63 (17–91) |
Sex | |
Male | 53 (67.1%) |
Stage prior to initial brain metastasis, | |
I/II | 13 (16.4%) |
III | 13 (16.4%) |
IV (M1a) | 6 (7.6%) |
IV (M1b) | 8 (10.1%) |
IV (M1c) | 25 (31.6%) |
Unknown primary melanoma/Data not available | 14 (17.7%) |
Intracranial site of metastasisa | |
Cerebrum | 72 (91.1%) |
Cerebellum | 17 (21.5%) |
Pons | 7 (8.9%) |
Leptomeninges | 2 (2.5%) |
Unknown | 1 (1.3%) |
Number of brain metastasisa | |
1 | 39 (49.4%) |
2–3 | 15 (19%) |
4–5 | 6 (7.6%) |
6–9 | 3 (3.8%) |
≥ 10 | 12 (15.2%) |
Unknown | 4 (5.0%) |
Size of the largest brain metastasisa | |
≤ 10 mm | 25 (31.7%) |
> 10–30 mm | 32 (40.5%) |
> 30–50 mm | 15 (19.0%) |
> 50 mm | 3 (3.8%) |
Unknown | 4 (5.0%) |
Symptomatic from brain metastasis | |
Yes | 36 (45.6%) |
Sites of extracranial metastatic organsa | |
Lung | 22 (27.9%) |
LN/Soft tissue | 21 (26.6%) |
Skin/SQ | 15 (19.0%) |
Bone | 12 (15.2%) |
Liver | 8 (10.1%) |
Adrenal gland | 3 (3.8%) |
V600 BRAF mutation | |
Mutated | 29 (36.7%) |
Wild type | 38 (48.1%) |
Unknown | 12(15.2%) |
Number of systemic therapy given after a diagnosis of brain metastasis | |
1 | 28 (35.4%) |
2 | 22 (27.8%) |
3+ | 20 (25.3%) |
Info not available | 9 (11.4%) |
Type of systemic therapy given after a diagnosis of brain metastasis | |
Ipilimumab | 39 (49.4%) |
Anti PD-1 antibody | 28 (35.4%) |
Concurrent Nivolumab/Ipilimumab | 8 (10.1%) |
BRAF inhibitor (+/− MEK inhibitor) only | 24 (30.4%) |
Cytotoxic chemotherapy | 35 (44.3%) |
Interleukin-2-based biochemotherapy | 10 (12.7%) |
Sequence of novel drug therapy after a diagnosis of brain metastasisb | |
Checkpoint inhibitor followed by BRAF inhibitor (+/− MEK inhibitor) | 11 (13.9%)b |
BRAF inhibitor (+/− MEK inhibitor) followed by checkpoint inhibitor | 3 (3.8%)b |